KCP
EDIT icon

Kera Capital Partners’s Editas Medicine EDIT Stock Holding History

Kera Capital Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.5K Sell
10,019
-710
-7% -$2.08K ﹤0.01% 632
2026
Q1 		$26.5K Buy
10,729
+637
+6% +$1.35K ﹤0.01% 567
2025
Q4 		$20.1K Hold
10,092
– – ﹤0.01% 550
2025
Q3 		$35K Hold
10,092
– – 0.01% 419
2025
Q2 		$22.2K Sell
10,092
-553
-5% -$905 ﹤0.01% 350
2025
Q1 		$12.3K Sell
10,645
-442
-4% -$650 ﹤0.01% 186
2024
Q4 		$14.1K Buy
+11,087
New +$28.3K ﹤0.01% 157

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Kera Capital Partners's EDIT Position: Q2 2026 in Review

Kera Capital Partners reduced its Editas Medicine (EDIT) stake by 6.6% in Q2 2026, selling an estimated $2.08K and leaving 10,019 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #632.

Kera Capital Partners first reported a position in EDIT in Q4 2024 and has held it in 7 quarters since. The position peaked at $35K in Q3 2025. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Kera Capital Partners held 10,019 shares of Editas Medicine worth $32.5K as of Q2 2026.
  • Kera Capital Partners sold 710 Editas Medicine shares in Q2 2026, an estimated $2.08K.
  • Editas Medicine made up ﹤0.01% of Kera Capital Partners's portfolio in Q2 2026, its #632 holding.
  • Kera Capital Partners first reported a position in Editas Medicine in Q4 2024 and has held it in 7 quarters since.
  • Kera Capital Partners's Editas Medicine position peaked at $35K in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.